Patents by Inventor Mark Dewhirst
Mark Dewhirst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240042233Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: July 27, 2023Publication date: February 8, 2024Applicants: Immunolight, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, JR., Mark DEWHIRST, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Patent number: 11865359Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: GrantFiled: December 27, 2019Date of Patent: January 9, 2024Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Publication number: 20220226666Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.Type: ApplicationFiled: March 21, 2022Publication date: July 21, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20220193090Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.Type: ApplicationFiled: March 10, 2022Publication date: June 23, 2022Inventors: Kathleen Ashcraft, Mark Dewhirst, Ines Batinic-Haberle, James D. Crapo
-
Patent number: 11305131Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: August 29, 2019Date of Patent: April 19, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 11285162Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.Type: GrantFiled: April 4, 2018Date of Patent: March 29, 2022Assignees: BioMimetix JV, LLC, Duke UniversityInventors: Kathleen Ashcraft, Mark Dewhirst, Ines Batinic-Haberle, James D. Crapo
-
Patent number: 11207409Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: GrantFiled: May 30, 2018Date of Patent: December 28, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
-
Publication number: 20210106594Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.Type: ApplicationFiled: April 4, 2018Publication date: April 15, 2021Inventors: Kathleen Ashcraft, Mark Dewhirst, Ines Batinic-Haberle, James D. Crapo
-
Publication number: 20200222711Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: December 27, 2019Publication date: July 16, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. Bourke, JR., Zakaryae Fathi, Wayne F. Beyer, JR., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Publication number: 20200009398Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
-
Patent number: 10441810Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: February 16, 2017Date of Patent: October 15, 2019Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 10253367Abstract: The present disclosure provides methods and kits for using biomarkers for predicting treatment response, determining likely survival rate, and/or determining aggressiveness of conditions such as Locally Advanced Breast Cancer (LABC) and Inflammatory Breast Cancer (IBC) in a subject.Type: GrantFiled: February 10, 2014Date of Patent: April 9, 2019Assignee: DUKE UNIVERSITYInventors: Sharareh Reihani, Mark Dewhirst, Kouros Owzar, Oana Craciunescu
-
Publication number: 20180344850Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: ApplicationFiled: May 30, 2018Publication date: December 6, 2018Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Mark DEWHIRST, Neil SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA, Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER
-
Patent number: 9937178Abstract: Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.Type: GrantFiled: December 7, 2012Date of Patent: April 10, 2018Assignee: Duke UniversityInventors: Sally Kornbluth, Manabu Kurokawa, Neil Spector, Mark Dewhirst
-
Patent number: 9771620Abstract: The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serous carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC.Type: GrantFiled: May 20, 2014Date of Patent: September 26, 2017Assignee: Duke UniversityInventors: Sharareh Reihani, Angeles Alvarez Secord, Mark Dewhirst, Chen Jiang, Kouros Owzar
-
Publication number: 20170157418Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: ApplicationFiled: February 16, 2017Publication date: June 8, 2017Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER, Frederic A. BOURKE, JR., Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
-
Patent number: 9649832Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: January 9, 2015Date of Patent: May 16, 2017Assignees: Immunolight, LLC, Duke UniversityInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr., Ian Stanton, Jennifer Ayres, Joshua T. Stecher, Michael Therien, Eric Toone, Dave Gooden, Mark Dewhirst, Joseph A. Herbert, Diane Fels, Katherine S. Hansen
-
Publication number: 20150246521Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: ApplicationFiled: January 9, 2015Publication date: September 3, 2015Applicants: lmmunolight, LLC, Duke UniversityInventors: Zakaryae FATHI, James CLAYTON, Harold WALDER, Frederic A. BOURKE, JR., Ian STANTON, Jennifer AYRES, Joshua T. STECHER, Michael THERIEN, Eric TOONE, Dave GOODEN, Mark DEWHIRST, Joseph A. HERBERT, Diane FELS, Katherine S. HANSEN
-
Patent number: 9023249Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: May 6, 2011Date of Patent: May 5, 2015Assignees: Immunolight, LLC, Duke UniversityInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr., Ian Stanton, Jennifer Ayres, Joshua T. Stecher, Michael Therien, Eric Toone, Dave Gooden, Mark Dewhirst, Joseph A. Herbert, Diane Fels, Katherine S. Hansen
-
Patent number: 8946289Abstract: Provided are manassantin compounds and methods of using the compounds. Provided are methods of treating a disease, the method comprising administering a compound according to Formula I. Further provided are pharmaceutical compositions comprising compounds according to Formula I. Also provided are methods of inhibiting HIF-1 in a cell, the methods comprising administering to the cell a compound according to Formula I.Type: GrantFiled: November 19, 2009Date of Patent: February 3, 2015Assignee: Duke UniversityInventors: Jiyong Hong, Mark Dewhirst, Hyoungsu Kim, Amanda C. Kasper, Eui Jung Moon, Yongho Park, Ceshea M. Wooten